IADR Abstract Archives
Salivary Opiorphin is Dependent of Pain Intensity in Chronic TMD Patients
Objectives: Opiorphin is pentapeptide that inhibits pain perception in humans. It can be isolated from body fluids, including saliva. The cause of temporomandibular disorders (TMD), the most common orofacial painful condition of non-dental origin, is largely unknown. The aim of the study was to measure the level of opiorphin in whole unstimulated saliva in chronic TMD patients and to compare the results with healthy control group. We hypothesized that higher opiorphin levels, due to reaction to chronic pain, can be expected in TMD patients, and that opiorphin levels would differ among patients depending of pain intensity, determined using graded chronic pain scale.
Methods: Saliva samples were obtained from 13 high pain intensity (HPI) TMD patients, 9 low pain intensity (LPI) TMD patients, and 11 pain-free control subjects. The presence of TMD was determined by DC/TMD questionnaire. Originally developed and validated LC-MS/MS method was used for opiorphin quantification.
Results: There was no statistically significant difference in age (F=0.06, p=0.94) between the three groups. The mean pain intensity for the LPI group was 37.88 while for the HPI group, it was 66.75 and statistically different (p=0.013). The average concentration of opiorphin in HPI, LPI and control group were 3.23, 0.93 and 1.35 pg/ul, respectively and differ significantly between groups (Kruskal-Wallis H test p=0.013). Opiorphin in HPI TMD patients was significantly higher, compared to LPI patients (Z=-2.87; p=0.004) and to control (p<0.05). Opiorphin levels of LPI TMD and control patients did not differ significantly.
Conclusions: We found significant increase of opiorphin in saliva of chronic TMD patients with high pain intensity, compared both to control group and to low intensity pain patients. Increased opiorphin secretion rate probably occurs secondary to chronic pain stimuli, and seems to be dose-dependent on the stimulus size. Study showed similar pattern of opiorphin behavior as we previously observed in burning mouth syndrome.
Methods: Saliva samples were obtained from 13 high pain intensity (HPI) TMD patients, 9 low pain intensity (LPI) TMD patients, and 11 pain-free control subjects. The presence of TMD was determined by DC/TMD questionnaire. Originally developed and validated LC-MS/MS method was used for opiorphin quantification.
Results: There was no statistically significant difference in age (F=0.06, p=0.94) between the three groups. The mean pain intensity for the LPI group was 37.88 while for the HPI group, it was 66.75 and statistically different (p=0.013). The average concentration of opiorphin in HPI, LPI and control group were 3.23, 0.93 and 1.35 pg/ul, respectively and differ significantly between groups (Kruskal-Wallis H test p=0.013). Opiorphin in HPI TMD patients was significantly higher, compared to LPI patients (Z=-2.87; p=0.004) and to control (p<0.05). Opiorphin levels of LPI TMD and control patients did not differ significantly.
Conclusions: We found significant increase of opiorphin in saliva of chronic TMD patients with high pain intensity, compared both to control group and to low intensity pain patients. Increased opiorphin secretion rate probably occurs secondary to chronic pain stimuli, and seems to be dose-dependent on the stimulus size. Study showed similar pattern of opiorphin behavior as we previously observed in burning mouth syndrome.